{
    "medicine_id": "faefdd16100d810a73a87b68de4fc65c7cba8b6d",
    "platform_id": "DB14505",
    "metadata": {
        "name": "Calcemin Advance 1 g 100mL Emulsion",
        "composition": "1 g 100mL Sodium borate",
        "clinical_particulars": {
            "therapeutic_indications": "No FDA or EMA approved therapeutic indications on its own",
            "contraindications": {
                "disease": "The acute oral LD sub 50 sub in rats is 4500 5000 mg kg and the intradermal LD sub 50 sub in rabbits is 10 000 mg kg L14450 Individuals are likely to be exposed to boric acid from industrial manufacturing or processing Local tissue injury from boric acid exposure is likely due to caustic effects Systemic effects from boric acid poisoning usually occur from multiple exposures over a period of days and involve gastrointestinal dermal CNS and renal manifestations Gastrointestinal toxicity include persistent nausea vomiting diarrhea epigastric pain hematemesis and blue green discoloration of the feces and vomit L2140 Following the onset of GI symptoms a characteristic intense generalized erythroderma follows L2140 Management of mild to moderate toxicity should be supportive In case of severe toxicity dialysis may be required in addition to supportive treatment",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Boric acid exhibits minimal bacteriostatic and antifungal activities L2140 Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures A32457",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}